NASDAQ · FBRX
Forte Biosciences, Inc.
$76.99$0.00 (0.0%)
Forte Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
Loading market information…
NASDAQ · CTOR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Citius Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Citius Oncology, Inc.’s next earnings report is currently expected on Dec 17, 2026, with estimated earnings per share of -$0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Citius Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q1 2025 | Feb 14, 2025 | -$0.09-50.0% vs estimate | $0.00 |
|---|
| Q4 2024 | Dec 27, 2024 | -$0.07+10.33% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$76.99$0.00 (0.0%)
Forte Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
$20.91+$0.26 (+1.26%)
Vor Biopharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.86% below the high.
$2.17$0.00 (0.0%)
Fate Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.82% below the high.
$4.19+$0.02 (+0.48%)
Owlet, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.27% below the high.
$5.97+$0.05 (+0.84%)
LENSAR Inc’s quoted price sits in the lower half of its reported 52-week range, 53.86% below the high.
$1.11-$0.06 (-5.13%)
Spero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.96% below the high.
$1.95+$0.16 (+8.94%)
Seres Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
$0.10+$0.00 (0.0%)
Applied Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.13% below the high.
